Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study

Rodríguez-Gutiérrez, René; Lavalle-González, Fernando J; Martínez-Garza, Laura E; Landeros-Olvera, Erick; López-Alvarenga, Juan C; Torres-Sepúlveda, Maria R; González-González, Jose G; Mancillas-Adame, Leonardo G; Salazar-Gonzalez, Bertha; Villarreal-Pérez, Jesus Z

doi:10.1186/1550-2783-9-22

Journal of the International Society of Sports Nutrition

Table 2 Baseline and End of Study Acylcarnitines in Controls and Cases

From: Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study

	Baseline		p+	End of the Study		p+	A vs C‡	B vs D‡
	Control (A) n = 15	Case (B) n = 17		Control (C) n = 15	Case (D) n = 17
C0	30.20 (24.80–34.31)	30.40 (28.21–35.58)	0.42	30.10 (24.23–34.74)	29.40 (25.12–31.69)	0.61	0.20	0.0008*
C2	8.23 (6.02–9.94)	7.21 (5.61–11.98)	0.94	6.78 (5.77–9.79)	6.89 (5.47–10.29)	0.95	0.22	0.24
C3	0.65 (0.54–0.82)	0.61 (0.49–0.74)	0.60	0.77 (0.64–0.93)	0.68 (0.50–0.84)	0.18	0.006*	0.35
C3DC	0.08 (0.07–0.10)	0.06 (0.04–0.08)	0.01*	0.08 (0.05–0.09)	0.06 (0.04–0.11)	0.89	0.38	0.32
C4	0.19 (0.14–0.20)	0.11 (0.07–0.16)	0.02*	0.18 (0.12–0.24)	0.13 (0.10–0.16)	0.10	0.27	0.48
C4DC	0.41 (0.25–0.56)	0.45 (0.33–0.53)	0.68	0.41 (0.30–0.53)	0.50 (0.33–0.54)	0.71	0.27	0.74
C5	0.14 (0.12–0.18)	0.12 (0.10–0.15)	0.77	0.16 (0.14–0.20)	0.19 (0.15–0.24)	0.06	0.63	0.050*
C5OH	0.20 (0.13–0.29)	0.25 (0.18–0.28)	0.48	0.22 (0.14–0.24)	0.24 (0.18–0.27)	0.29	0.59	0.96
C5:1	0.03 (0.02–0.4)	0.03 (0.02–0.5)	0.89	0.03 (0.02–0.06)	0.03 (0.02–0.05)	1.00	0.90	0.78
C5DC	0.09 (0.04–0.19)	0.09 (0.05–0.12)	0.40	0.08 (0.06–0.10)	0.08 (0.06–0.10)	0.18	0.48	0.14
C6	0.07 (0.04–0.09)	0.05 (0.04–0.08)	0.79	0.04 (0.03–0.08)	0.05 (0.03–0.07)	0.74	0.20	0.82
C6DC	0.07 (0.04–0.10)	0.06 (0.05–0.08)	0.25	0.06 (0.03–0.08)	0.06 (0.03–0.07)	0.82	0.22	0.78
C8	0.11 (0.07–0.14)	0.06 (0.04–0.07)	0.006*	0.09 (0.07–0.12)	0.10 (0.07–0.12)	0.79	0.20	0.039*
C10	0.07 (0.05–0.10)	0.07 (0.04–0.12)	0.71	0.06 (0.01–0.10)	0.05 (0.02–0.09)	0.04*	0.65	0.09
C10:1	0.09 (0.06–0.13)	0.08 (0.05–0.10)	0.34	0.07 (0.03–0.11)	0.08 (0.07–0.13)	0.41	0.15	0.61
C10:2	0.06 (0.01–0.10)	0.05 (0.02–0.09)	0.74	0.05 (0.03–0.10)	0.07 (0.03–0.10)	0.86	0.71	0.15
C12	0.07 (0.04–0.11)	0.07 (0.05–0.09)	0.66	0.07 (0.04–0.14)	0.08 (0.05–0.09)	0.61	0.38	0.30
C14	0.06 (0.04–0.09)	0.06 (0.05–0.08)	0.69	0.06 (0.04–0.10)	0.05 (0.05–0.09)	0.49	0.30	0.005*
C14:1	0.07 (0.02–0.10)	0.06 (0.05–0.08)	0.55	0.06 (0.05–0.09)	0.05 (0.04–0.10)	0.67	0.89	0.78
C14:2	0.03 (0.03–0.06)	0.04 (0.02–0.07)	0.49	0.05 (0.03–0.07)	0.03 (0.02–0.05)	0.12	0.30	0.17
C16	0.67 (0.52–0.67)	0.60 (0.50–0.73)	0.47	0.57 (0.45–0.68)	0.59 (0.50–0.68)	0.79	0.27	0.57
C160H	0.04 (0.02–0.05)	0.03 (0.03–0.05)	0.58	0.07 (0.04–0.09)	0.04 (0.02–0.05)	0.74	0.04*	0.37
C16:1	0.07 (0.06–0.10)	0.06 (0.03–0.08)	0.10	0.06 (0.05–0.07)	0.05 (0.04–0.07)	0.79	0.06	0.99
C16:1 OH	0.08 (0.06–0.09)	0.09 (0.07–0.11)	0.26	0.07 (0.04–0.09)	0.07 (0.05–0.10)	0.49	0.42	0.35
C18	0.37 (0.32–0.41)	0.31 (0.27–0.45)	0.24	0.36 (0.28–0.45)	0.28 (0.22–0.32)	0.27	0.80	0.03*
C18 OH	0.06 (0.03–0.10)	0.04 (0.03–0.08)	0.66	0.07 (0.03–0.11)	0.05 (0.03–0.11)	0.86	0.38	0.48
C18:1	0.64 (0.59–0.81)	0.74 (0.68–0.84)	0.13	0.64 (0.53–0.79)	0.73 (0.61–0.83)	0.24	0.76	0.92
C18:1 OH	0.03 (0.02–0.03)	0.02 (0.02–0.03)	0.42	0.02 (0.02–0.03)	0.02 (0.02–0.03)	0.95	0.84	0.43
C18:2	0.22 (0.18–0.33)	0.28 (0.22–0.32)	0.36	0.24 (0.21–0.28)	0.22 (0.17–0.30)	0.31	0.97	0.12

^All values are in μmol/l. Results are reported in Median and Confidence Interval 95%.
+p Values were calculated by Mann–Whitney Test.
‡p Values were calculated by Wilcoxon Rank Test.
* Significant Result p < 0.05.

Back to article page

ISSN: 1550-2783

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com